#United States #La Jolla #Precision Medicine #Acurion #OncoGaze

Acurion: A New Era in Precision Oncology

Acurion, the company formerly known as io9, has taken a significant step in its mission to revolutionize cancer treatment by officially unveiling its new brand identity, a fresh leadership team, and plans for upcoming fundraising. This rebranding represents a strategic pivot aimed at aligning the company more closely with its evolving goals and ambitions in precision medicine.

A Transformative Vision for Oncology

Dr. Scott Lippman, co-founder of Acurion and an esteemed figure in medical oncology, emphasized the urgency of their mission. He remarked, "Acurion's mission is to make precision medicine a reality for more cancer patients." He pointed out the challenges faced in oncology—the lengthy process from diagnosis to treatment can often lead to critical delays that jeopardize patient outcomes. Acurion aims to address these issues through its innovative approach designed to provide oncologists with actionable genomic insights, streamlining the path from diagnosis to treatment.

At the heart of Acurion's strategy is its proprietary artificial intelligence platform, OncoGaze™, which significantly accelerates the identification of genomic biomarkers from routine tumor biopsies. This groundbreaking technology reduces the waiting period from diagnosis to effective treatment from several weeks to an astonishing few seconds, making precision medicine more accessible worldwide. Web Cavenee, a prominent scientist and co-founder of Acurion, stated, "The promise of precision medicine has been hampered by the tissues and time required for genomic analysis. OncoGaze effectively mitigates these challenges."

A Leadership Team Poised for Success

To spearhead this exciting new chapter, Acurion has assembled a top-tier leadership team with extensive experience in life sciences, technology, and finance. The new CEO, Rick Fultz, boasts a rich background guiding companies in the life sciences sector toward sustainable growth. His expertise will be vital in steering Acurion through its next phase of innovation.

Other key members include Dr. Feng Cao, the Chief Operating Officer, who will manage Acurion's commercial growth along with regulatory strategies; Dr. Ludmil Alexandrov, the Chief Scientific Officer, who brings a depth of knowledge in cancer genomics; and Dr. Erik Bergstrom, the Chief Technology Officer, who leads the development of the OncoGaze platform. Financial operations will be overseen by Shelly Vandertie, Vice President of Finance, whose acumen in financial strategy will be instrumental for Acurion's growth.

Magda Marquet, co-founder and board chair, expressed her enthusiasm about Rick Fultz's leadership, noting his dynamic approach and commitment to enhancing patient care. Fultz, in turn, acknowledged the outstanding accomplishments of Acurion's scientists and staff, expressing his excitement to advance innovations in precision oncology alongside them.

Preparing for the Future: Series A Fundraising

With its leadership team firmly in place, Acurion is now looking to broaden its reach by establishing collaborations with academic institutions and patient advocacy networks. This effort will be boosted by the launch of their Series A fundraising, scheduled for April 15th. These funds will be crucial in supporting Acurion’s goal of expanding its operations and amplifying its innovative initiatives.

About Acurion

Acurion is on a mission to change how frontline cancer care is delivered. By equipping oncologists with vital genomic insights, the company facilitates quicker, more precise treatment decisions for cancer patients. The team is dedicated to speeding up the translation of their cutting-edge AI technologies into clinical practice, ultimately making significant strides in improving patient outcomes on a global scale. For more information about Acurion, visit www.acurionhealth.com.

In summary, Acurion is positioned to make a revolutionary impact on precision oncology, driven by a refreshed identity, an expert leadership team, and innovative technology that promises to redefine cancer care across the globe.